Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer

Toon, Christopher W.; Chou, Angela; Clarkson, Adele; DeSilva, Keshani; Houang, Michelle; Chan, Joseph C. Y.; Sioson, Loretta L.; Jankova, Lucy; Gill, Anthony J.
February 2014
PLoS ONE;Feb2014, Vol. 9 Issue 2, p1
Academic Journal
MYC over-expression as determined by molecular means has been reported as a favorable prognostic biomarker in colorectal carcinoma (CRC). However MYC expression analysis is not available in the routine clinical setting. We investigated whether immunohistochemistry (IHC) for the myc protein using a novel commercially available rabbit monoclonal antibody [clone Y69] which is currently in widespread clinical use for lymphoma diagnosis could be used to predict outcome in resected CRC. Myc IHC was performed on a tissue microarray (TMA) comprising a retrospective cohort of 1421 CRC patients and scored blinded as to all clinical and pathological data. IHC was also performed on a subcohort of whole section CRCs to assess staining characteristics and concordance with TMA expression. MYC over-expression was found in 980 (69%) of CRCs and was associated with tumor stage and DNA mismatch repair/BRAF status. There was substantial agreement between TMA and whole section myc IHC (kappa = 0.742, p<0.01). CRCs with MYC over-expression demonstrated improved 5-year survival (93.2% vs. 57.3%), with the effect significantly modulated by the dominant effect of tumor stage, age at diagnosis and lymphovascular space invasion status on survival. We conclude that myc status as determined by IHC alone can be used to predict overall survival in patients with CRC undergoing surgical resection.


Related Articles

  • Neutrophil-lymphocyte ratio as a predictive factor for tumor staging in colorectal cancer. ÖZGEHAN, Gülay; KAHRAMANCA, Şahin; KAYA, İsmail Oskay; BİLGEN, Köksal; BOSTANCI, Hasan; GÜZEL, Hakan; KÜÇÜKPINAR, Tevfik; KARGICI, Hülagü // Turkish Journal of Medical Sciences;2014, Vol. 44 Issue 3, p365 

    Background/aim: In the preoperative period, simple methods to identify the tumor stage of colorectal cancer patients are needed. In recent years, the neutrophil-lymphocyte ratio (NLR) has been used as a predictive parameter for systemic inflammatory response in many different clinical entities....

  • Accuracy of water-enema multidetector computed tomography (WE-MDCT) in colon cancer staging: a prospective study. Sibileau, E.; Ridereau-Zins, Catherine; Vanel, D.; Pavageau, A.; Bertrais, S.; Metivier-Cesbron, E.; Venara, A.; Aubé, C. // Abdominal Imaging;Oct2014, Vol. 39 Issue 5, p941 

    Purpose: To assess the accuracy of water-enema multidetector computed tomography (WE-MDCT) in extra-rectal colon cancer staging. Materials and methods: Fifty-three patients (mean age 70 years) with extra-rectal colon cancer proven by colonoscopy and biopsy were prospectively evaluated by...

  • Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test? Bresalier, Robert; Kopetz, Scott; Brenner, Dean // Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p664 

    Colorectal cancer is the second leading cause of cancer death in industrialized nations, accounting for 10 % of the total cancer burden with an individual lifetime risk of ~6 % in the USA (Siegel et al. in CA Cancer J Clin 62:9-29, , American Cancer Society in Colorectal cancer facts and figures...

  • Immunohistochemical analysis of retinoblastoma cell phenotype using neuronal and glial cell markers. ORELLANA, MARÍA EUGENIA; NETO, RUBENS BELFORT; ANTECKA, EMILIA; BURNIER JR., MIGUEL NOEL // Arquivos Brasileiros de Oftalmologia;nov/dez2016, Vol. 79 Issue 6, p395 

    Purpose: The cellular origin of retinoblastoma is uncertain as constituent tumor cells heterogeneously express markers of both immature and mature retinal cells. An immunohistochemical analysis of cellular origin may yield valuable insights into disease progression and treatment options. This...

  • Immunohistochemical Examination of Anti-STn Monoclonal Antibodies LLU9B4, B72.3, and B35.2 for Their Potential use as Tumor Markers. Keshab Pant; Ankur Jain; John McCracken; Kevin Thompson // Digestive Diseases & Sciences;Aug2008, Vol. 53 Issue 8, p2189 

    Abstract   Purpose Several investigators, including ourselves, have demonstrated by immunohistochemistry that in malignancy of colon, the tumor cells or cells adjacent to the tumor become reactive with anti-STn monoclonal antibodies, while in normal individuals the colonic cells do not...

  • Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. Slyskova, Jana; Naccarati, Alessio; Pardini, Barbara; Polakova, Veronika; Vodickova, Ludmila; Smerhovsky, Zdenek; Levy, Miroslav; Lipska, Ludmila; Liska, Vaclav; Vodicka, Pavel // Mutagenesis;Jul2012, Vol. 27 Issue 4, p519 

    No abstract available.

  • Clinical significance of perineural invasion diagnosed by immunohistochemistry with anti-S100 antibody in Stage I-III colorectal cancer. Shimada, Yoshifumi; Kido, Tomoki; Kameyama, Hitoshi; Nakano, Mae; Yagi, Ryoma; Tajima, Yosuke; Okamura, Takuma; Nakano, Masato; Nagahashi, Masayuki; Kobayashi, Takashi; Minagawa, Masahiro; Kosugi, Shin-ichi; Wakai, Toshifumi; Ajioka, Yoichi // Surgery Today;Dec2015, Vol. 45 Issue 12, p1493 

    Purpose: Perineural invasion (PN) diagnosed by hematoxylin-eosin (HE) staining is an important prognostic factor after curative-intent surgery in patients with colorectal cancer. However, the clinical significance of PN diagnosed by immunohistochemistry (IHC) has not been investigated. The...

  • Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Nakanishi, Ryota; Harada, Jun; Tuul, Munkhbold; Zhao, Yan; Ando, Koji; Saeki, Hiroshi; Oki, Eiji; Ohga, Takefumi; Kitao, Hiroyuki; Kakeji, Yoshihiro; Maehara, Yoshihiko // International Journal of Clinical Oncology;Dec2013, Vol. 18 Issue 6, p1042 

    Background: Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor. Methods: In this retrospective study,...

  • What an abnormal FIT result really means. Telford, Jennifer J. // British Columbia Medical Journal;Mar2014, Vol. 56 Issue 2, p97 

    The article discusses British Columbia's Colon Screening Program that was introduced in November 2013 and offers colorectal cancer screening to asymptomatic patients aging 50-74 through the fecal immunochemical test.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics